Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection

Area of Science:

• Dermatology
• Hepatology
• Pharmacology

Background:

• Hepatitis C virus (HCV) infection is associated with various dermatological conditions.
• Antiviral therapies, such as interferon-alpha (IFN), can exacerbate or trigger skin lesions in HCV patients.

Observation:

• Two dark-skinned patients receiving combination therapy with interferon-alpha and ribavirin presented with new-onset hyperpigmentation.
• Affected areas included the skin and, notably, the tongue, a manifestation not previously documented.

Findings:

• Immunohistochemical analysis of tongue biopsies confirmed the presence of melanin deposits in the hyperpigmented regions.
• The study suggests a potential mechanism involving enhanced melanocyte activity stimulated by interferon therapy.

Implications:

• This finding expands the spectrum of known cutaneous side effects associated with interferon-based treatments for Hepatitis C.
• Clinicians should be aware of the possibility of hyperpigmentation, particularly in dark-skinned individuals undergoing antiviral therapy.